Maryam Shariati

The University of Texas Health Science Center at Houston — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

12h-index1.8kcitations52works0.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer-related molecular mechanisms research(16), Cancer Cells and Metastasis(15), Genetic factors in colorectal cancer(11), FOXO transcription factor regulation(9), Advanced Breast Cancer Therapies(8)

Publications52 total

Imaging resistance to anti-androgens in prostate cancer by multimodal 13C-pyruvate hyperpolarized magnetic resonance spectroscopy and 18F-pivalate positron emission tomography
Nuclear Medicine and Biology·2025Open Access
Data from Oxidative Phosphorylation Is a Metabolic Vulnerability in Chemotherapy-Resistant Triple-Negative Breast Cancer
2023Open Access
Supplementary Data from Oxidative Phosphorylation Is a Metabolic Vulnerability in Chemotherapy-Resistant Triple-Negative Breast Cancer
2023Open Access
Data from Oxidative Phosphorylation Is a Metabolic Vulnerability in Chemotherapy-Resistant Triple-Negative Breast Cancer
2023Open Access
Supplementary Data from Oxidative Phosphorylation Is a Metabolic Vulnerability in Chemotherapy-Resistant Triple-Negative Breast Cancer
2023Open Access
Supplementary Figure 3 from FOXC2 Expression Links Epithelial–Mesenchymal Transition and Stem Cell Properties in Breast Cancer
2023Open Access
Supplementary Figure 3 from FOXC2 Expression Links Epithelial–Mesenchymal Transition and Stem Cell Properties in Breast Cancer
2023Open Access
Supplementary Figure 4 from FOXC2 Expression Links Epithelial–Mesenchymal Transition and Stem Cell Properties in Breast Cancer
2023Open Access
Supplementary Figure 1 from FOXC2 Expression Links Epithelial–Mesenchymal Transition and Stem Cell Properties in Breast Cancer
2023Open Access
Data from FOXC2 Expression Links Epithelial–Mesenchymal Transition and Stem Cell Properties in Breast Cancer
2023Open Access
Data from FOXC2 Expression Links Epithelial–Mesenchymal Transition and Stem Cell Properties in Breast Cancer
2023Open Access
Supplementary Figure 2 from FOXC2 Expression Links Epithelial–Mesenchymal Transition and Stem Cell Properties in Breast Cancer
2023Open Access
Supplementary Materials and Methods from FOXC2 Expression Links Epithelial–Mesenchymal Transition and Stem Cell Properties in Breast Cancer
2023Open Access
Supplementary Figure 4 from FOXC2 Expression Links Epithelial–Mesenchymal Transition and Stem Cell Properties in Breast Cancer
2023Open Access
Supplementary Figure 1 from FOXC2 Expression Links Epithelial–Mesenchymal Transition and Stem Cell Properties in Breast Cancer
2023Open Access
Supplementary Figure 2 from FOXC2 Expression Links Epithelial–Mesenchymal Transition and Stem Cell Properties in Breast Cancer
2023Open Access
Supplementary Materials and Methods from FOXC2 Expression Links Epithelial–Mesenchymal Transition and Stem Cell Properties in Breast Cancer
2023Open Access
Oxidative Phosphorylation Is a Metabolic Vulnerability in Chemotherapy-Resistant Triple-Negative Breast Cancer
Cancer Research·2021· 146 citedOpen Access
Combined inhibition of DDR1 and CDK4/6 induces synergistic effects in ER-positive, HER2-negative breast cancer with PIK3CA/AKT1 mutations
Oncogene·2021· 19 cited
N-BLR, a primate-specific non-coding transcript leads to colorectal cancer invasion and migration
UNC Libraries·2020Open Access
page 1 of 3Next →

Frequent Co-authors

Sendurai A. Mani(29), Kurt W. Evans(22), Steven J. Werden(16), Joseph H. Taube(16), Tapasree Roy Sarkar(16), Nathalie Sphyris(16), Jeffrey T. Chang(16), Jeffrey M. Rosen(16), Brett G. Hollier(14), Agata A. Tinnirello(14), Sreedevi V. Kumar(14), Venkata Lokesh Battula(14), Rudy Guerra(14), Naoyuki Miura(14), Funda Meric‐Bernstam(14), Riccardo Spizzo(13), Milena S. Nicoloso(13), Masayoshi Shimizu(13), Roxana S. Redis(13), Roberta Gafà(13)